Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma

Melamed, Samuel; Chow, Pierce K. H.; Shih-Yen, Edwin Chan; Machin, David; Soo, Khee‐Chee

doi:10.1002/14651858.cd001199.pub2

Cited by 113 publications

(91 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although all but one case with gross vascular invasion suspected recurrence after HCC resection is important because there is currently no effective adjuvant or neoadjuvant therapy (30). In this regard, we believe that our results demonstrated that a prediction model that uses preoperative MR imaging has the potential to preoperatively identify high-risk patients, for whom other treatment modalities such as liver transplantation or a wider extent of resection can be considered.…”

Section: Discussionmentioning

confidence: 63%

Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection

An¹,

Kim

Park³

et al. 2015

Radiology

178

130

View full text Add to dashboard Cite

Purpose:To identify magnetic resonance (MR) imaging features that enable prediction of early recurrence (,2 years) after curative resection of hepatocellular carcinoma (HCC) and to derive a preoperative prediction model. Materials and Methods:This retrospective study was approved by the institutional review board. The requirement to obtain written informed consent was waived. A total of 268 patients who underwent hepatic resection for a single HCC from January 2008 to August 2011 were divided into two cohorts: a training cohort, which was used to derive a prediction model (n = 187), and a validation cohort (n = 81). All MR images from the training cohort were reviewed by two radiologists. A prediction model was constructed by using MR imaging features that were independently associated with early recurrence with use of multiple logistic regression analysis. The performance of the prediction model in the validation cohort was evaluated with respect to discrimination (ie, whether the relative ranking of individual predictions of subsequent early recurrence is in the correct order). Results:In the training cohort, four MR imaging features were independently associated with early recurrence: rim enhancement (odds ratio [ Conclusion:The prediction model derived from rim enhancement, peritumoral parenchymal enhancement, satellite nodule, and tumor size can be used preoperatively to estimate the risk of early recurrence after resection of a single HCC.q RSNA, 2015

show abstract

Section: Discussionmentioning

confidence: 63%

Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection

An¹,

Kim

Park³

et al. 2015

Radiology

178

130

View full text Add to dashboard Cite

show abstract

“…Currently, the conclusive role of adjuvant therapy following curative resection of HCC remains to be defined (Samuel et al 2009). Nevertheless, several adjuvant strategies have been tested in clinical trials, including systemic and intra-arterial chemotherapy, intraarterial radiolabeled lipiodol, TACE, acyclic retinoids, interferon, adoptive immunotherapy, autologous tumor vaccine, and, more recently, sorafenib (Xie et al 2012;Furtado et al 2014).…”

Section: Adjuvant Therapy After Surgical Resectionmentioning

confidence: 99%

Treatment of Liver Cancer

Liu

Chen

2015

Cold Spring Harb Perspect Med

279

198

View full text Add to dashboard Cite

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.

show abstract

“…3 Limited adjuvant therapies are available for advanced HCC patients. 4,5 Sorafenib, a Raf-1 kinase inhibitor, was reported to extend patient survival for nearly 3 months. 6 However, a recent multicenter, double-blinded trial concluded that sorafenib did not extend recurrence-free survival, but increased adverse effects of the treatment, 3 and the findings are consistent with a growing list of negative reports from primary or adjuvant use after resection, ablation, or transarterial chemoembolization.…”

mentioning

confidence: 99%

Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter

Ding

Xiao

Zou

et al. 2017

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma

Abstract: Does quality of reports of randomised trials a ect estimates of intervention e icacy reported in meta-analyses?. Lancet 1998;352:609-13. Nagourney 1987 Nagourney DM, Adson M. Major hepatic resections for hepatoma in the West. In: Wanebo HJ editor(s). Hepatic and Biliary Cancer.

Cited by 113 publications

References 30 publications

Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection

Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection

Treatment of Liver Cancer

Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter

Contact Info

Product

Resources

About